Papers from the Japanese Surgical SocietyPrognostic significance of serum p53 antibody in patients with esophageal squamous cell carcinoma*,☆☆
Section snippets
Patients
A total of 105 consecutive patients with primary esophageal squamous cell carcinoma were enrolled in this study. Patients included 92 men (88%) and 13 women (12%) with a median age of 65 years (range, 40 to 87 years). They were surgically treated at Chiba University Hospital between April 1997 and December 2000. TNM classification13 was established on the basis of pathologic examinations of resected specimens. Among 105 patients, 50 patients had stage I disease, 24 had stage II, 21 had stage
Titer of serum p53-Ab and conventional tumor markers in patients with esophageal squamous cell carcinoma
Serum p53-Ab levels in 105 patients with primary esophageal squamous cell carcinoma were significantly higher than those in healthy control subjects (median 0.35 U/mL, range 0 to 168 U/mL vs median 0.20 U/mL, range 0 to 2.6 U/mL, P <.001). On the basis of comparison to the 95% range of distribution of serum p53-Ab titers in healthy control subjects, a cutoff value was determined as 1.3 U/mL. Thus, 28 of the 105 (26.7%) patients were positive for serum p53-Abs. The positivity rate for patients
Discussion
Tumor markers are supportive for establishing diagnosis, estimating prognosis, monitoring treatment, detecting recurrence, and screening. In comparison to other malignancies of the gastrointestinal tract, there are few suitable biomarkers for esophageal squamous cell carcinoma.14, 15
We investigated the clinicopathologic significance of serum p53-Abs in patients with esophageal cancer. In this study, positivity rate for detecting esophageal cancer was 27% for patients overall and 20% for
References (25)
- et al.
Serum p53 antibodies in small cell lung cancer: the lack of prognostic relevance
Lung Cancer
(2001) - et al.
Multi factorial analysis of p53 alteration in human cancer: a review
Int J Cancer
(1994) - et al.
Frequent mutation of the p53 gene in human esophageal cancer
Proc Natl Acad Sci
(1990) - et al.
p53 protein accumulation and p53 gene mutation in esophageal carcinoma
Cancer
(1997) - et al.
p53 protein expression and prognosis in squamous cell carcinoma of the esophagus
Cancer
(1994) - et al.
p53 sequence analysis predicts treatment response and outcome of patients with esophageal carcinoma
Cancer
(1998) - et al.
Circulating anti-p53 antibodies in esophageal cancer patients are found predominantly in individuals with p53 core domain mutations in their tumors
Cancer Res
(1996) - et al.
Serum anti-p53 antibodies in patients with squamous cell carcinoma of the esophagus: comparison with p53 alterations and lymph node invasion
Int J Oncol
(1997) - et al.
Detection of serum p53 antibodies in patients with esophageal squamous cell carcinoma: correlation with clinicopathologic features and tumor markers
Oncol Rep
(1998) - et al.
A study on p53 protein and anti-p53 antibodies in the sera of patients with esophageal cancer
Mutat Res
(1998)
Circulating p53 antibodies, p53 gene mutational profile and product accumulation in esophageal squamous cell carcinoma in India
Int J Cancer
Cited by (59)
Clinical practice guidelines for molecular tumor marker, 2nd edition review part 2
2024, International Journal of Clinical OncologyClinical practice guidelines for molecular tumor markers, 2nd edition review part 1
2024, International Journal of Clinical OncologyAssociation between serum baseline C1q and IgG levels and the efficacy of combined immunotherapy in patients with esophageal squamous cell carcinoma: a retrospective study
2023, Immunopharmacology and Immunotoxicology
- *
Supported in part by a Grant-in-Aid from the Ministry of Education, Science and Culture of Japan (Advanced Medicine Development Project and #12671200).
- ☆☆
Reprint requests: Hideaki Shimada, MD, Department of Academic Surgery, Chiba University Graduate School of Medicine, 1-8-1 Inohana Chuou-ku, Chiba 260-8677, Japan.